Stand Up To Cancer - standup2cancer.orgThis is where the end of cancer begins
   Please leave this field empty

SU2C Scientific Research Teams

Share this:
Email

Like this page on Facebook

Drew M. Pardoll, M.D., Ph.D.

Scientific Research Team:
Drew M. Pardoll, M.D., Ph.D.

Drew M. Pardoll, M.D., Ph.D.

Pardoll is an Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at the Johns Hopkins University, School of Medicine. He is director of the Cancer Immunology in the Sidney Kimmel Comprehensive Cancer Center. 
Pardoll completed his medical and doctorate degree, and Medical Residency and Oncology Fellowship at Johns Hopkins University. 

Pardoll has published over 250 papers as well as over 20 book chapters on the subject of T cell immunology and cancer vaccines. He has served on the editorial board of the Journal of the National Cancer Institute and Cancer Cell, and has served as a member of scientific advisory boards for the Cancer Research Institute, the University of Pennsylvania Human Gene Therapy Gene Institute, Biologic Resources Branch of the National Cancer Institute, Harvard-Dana Farber Cancer Center, Cerus Corporation, Global Medical Products Corporation, Genencor Corporation, CellGenesys Corporation, Mojave Therapeutics, the American Association of Clinical Oncology and the American Association of Cancer Research. 

Pardoll has made a number of basic advances in Cellular Immunology, including the discovery of gamma - delta T cells, NKT cells and interferon-producing killer dendritic cells. Over the past two decades, he has studied molecular aspects of dendritic cell biology and immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. He is an inventor of a number of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes based cancer vaccines. Pardoll’s basic immunology discoveries include the identification of γδ-T cells, NKT cells and IKDC. He elucidated the role of Stat3 signaling in tumor immune evasion and in Th17 development, leading to the discovery that Stat3-driven Th17 responses promote carcinogenesis. Pardoll discovered one of the two ligands for the PD-1 inhibitory receptor and leads the Hopkins cancer immunology program that developed PD-1 pathway-targeted antibodies, demonstrating their clinical activity in multiple cancer types. His more than 250 articles cover cancer vaccines, gene therapies, cancer prevention technologies, and recombinant immune modulatory agents for specific pathways that regulate immunity to cancer and infectious diseases.

...that in 2014, cancer will be the leading cause of death in the world?